



Application Ser. No.: 10/761,982
 Filing Date: January 21, 2004
 Examiner: Stockton, Laura

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound of formula (1) or formula (2)



wherein:

X and Y independently are N or CH wherein ~~at least one of X and Y is N;~~

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NO₂, NH(C₁-C₄)alkyl and N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, ~~or~~
~~5- or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho~~

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

~~carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N;~~

Z is H, 4-aminophenyl, SO_2R_3 or COR_3 wherein R_3 is $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_3\text{-C}_6)$ cycloalkyl, Ar as defined above, $(\text{C}_2\text{-C}_6)$ alkenyl or $(\text{C}_2\text{-C}_6)$ alkynyl;

R_1 is H, $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_3\text{-C}_6)$ cycloalkyl or Ar as defined above;

R' is H or $(\text{C}_1\text{-C}_4)$ alkyl; and

when Z is H, R_2 is a selected from the group consisting of:

cyano,

$\text{C}(\text{O})\text{-ORa}_1$ wherein Ra_1 is methyl, ethyl or isopropyl,

$\text{C}(\text{O})\text{-NHRa}_2$ wherein Ra_2 is cyclopropyl,

$\text{C}(\text{O})\text{-N}(\text{Ra}_2')$, wherein $\text{N}(\text{Ra}_2')$ is aziridinyl or azetidiny, optionally substituted with $(\text{C}_1\text{-C}_4)$ alkyl or Ar as defined above,

$\text{C}(\text{O})\text{-N}(\text{Ra}_3)\text{-ORa}_3$ wherein each Ra_3 may be identical or different and each Ra_3 is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

$\text{C}(\text{O})\text{Ra}_4$ wherein Ra_4 is Ar as defined above or $(\text{C}_3\text{-C}_5)$ cycloalkyl optionally substituted with $(\text{C}_1\text{-C}_4)$ alkyl or Ar as defined above,

$\text{C}(\text{Ra}_4)\text{=N-Rb}$ wherein:

Ra_4 is H, Ar as defined above, or $(\text{C}_3\text{-C}_5)$ cycloalkyl optionally substituted with $(\text{C}_1\text{-C}_4)$ alkyl or Ar as defined above, and

Rb is $(\text{C}_1\text{-C}_2)$ alkyl, $(\text{C}_3\text{-C}_5)$ cycloalkyl, hydroxyl, $(\text{C}_1\text{-C}_4)$ alkoxy, $(\text{C}_2\text{-C}_4)$ alkenyloxy, or $(\text{C}_1\text{-C}_4)$ alkylenoxy wherein said $(\text{C}_1\text{-C}_4)$ alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, $(\text{CH}_2)_n\text{Ar}$ wherein n is 0 or 1 and Ar is as defined above, $(\text{C}_1\text{-C}_4)$ alkoxy, NH_2 , $\text{NH}(\text{C}_1\text{-C}_4)$ alkyl, and $\text{N}((\text{C}_1\text{-C}_4)\text{alkyl})_2$ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

may optionally contain a second hetero atom selected from the group consisting of O, S and N,
NH-C(O)Ra₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,
NHRa₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above, phenyl, and
5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and
when Z is SO₂R₃ or COR₃, R₂ is carboxyl, NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ or (C₃-C₅)cycloalkylamino; or
a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or
a ~~pharmaceutically~~ pharmaceutically acceptable salt of the compound of formula (1) or formula (2).

2. (original) The compound according to claim 1 wherein Ar is phenyl, 4-fluorophenyl or 4-methoxyphenyl.

3. (original) The compound according to claim 2 wherein R₁ is H, (C₁-C₄)alkyl, phenyl or substituted phenyl.

4. (canceled).

5. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R₂ is C(O)-ORa₁ and wherein Ra₁ is (C₁-C₄)alkyl methyl, ethyl or isopropyl.

6. (original) The compound according to claim 5 selected from the group consisting of:

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

ethyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
isopropyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
methyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-
carboxylate,
ethyl 6-(+)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-
carboxylate,
ethyl 6-(R,S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6,6-bis(4-methoxyphenyl)-6,7-dihydro-1H-indazole-3-
carboxylate,
ethyl 6-(R,S)-6-(3,4-dimethoxyphenyl)-6-phenyl-6,7-dihydro-1H-
indazole-3-carboxylate,
ethyl 6-(R,S)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-
3-carboxylate,
ethyl (-)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-
carboxylate,
ethyl (+)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-
carboxylate,
ethyl 6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazole-3-
carboxylate, and
ethyl 7-methyl-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxylate.

7. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R₂ is CORa₄ and Ra₄ is Ar or (C₃-C₅)cycloalkyl.

8. (original) The compound according to claim 7 selected from the group consisting of:

cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)phenylmethanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)-(1H-pyrrol-3-yl)methanone,
6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(-)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(+)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone, and
cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone.

9. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R_2 is $C(O)-NHR_2$, $C(O)-N(R_3)-OR_3$ or $C(O)-N(R_2')$.

10. (original) The compound according to claim 9 selected from the group consisting of:

N-(cyclopropyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide,
azetidin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(N-methoxy-N-methyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide, and
aziridin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone.

11. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R_2 is $C(R_4)=N-R_b$.

12. (original) The compound according to claim 11 selected from the group consisting of:

Application Ser. No.: 10/761,982

Filing Date: January 21, 2004

Examiner: Stockton, Laura

(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)
methanone oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)
methanone oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)
methanone oxime,
(E,Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone oxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
oxime,
(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-
yl)methanone O-methyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone
O-methyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone
O-methyloxime,
(E,Z)6,6-diphenyl-6,6-dihydro-1H-indazole-3-carbaldehyde O-
methyloxime,
(E, Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-allyloxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-allyloxime,
(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-allyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-allyloxime,

Application Ser. No.: 10/761,982

Filing Date: January 21, 2004

Examiner: Stockton, Laura

(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(2-methoxyethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-methoxyethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-methoxyethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-benzylloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-benzylloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-benzylloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(4-nitrobenzyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(4-nitrobenzyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(4-nitrobenzyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(2-dimethylaminoethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-dimethylaminoethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-dimethylaminoethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(2-fluoroethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-fluoroethyl)oxime,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

(E)cyclopropyl[6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl]methanone
O-(2-fluoroethyl)oxime,
(E,Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-
1H-indazol-3-yl]methanone oxime,
(E)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(-)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(-)-6-(E)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(+)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(E,Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-
yl]methanone oxime,
(Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-
yl]methanone oxime, and
(E)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-
yl]methanone oxime.

13. (currently amended) The compound according to ~~claim 4~~ claim 3
wherein R₂ is NH-C(O)Ra₄.

14. (currently amended) The compound according to claim 13 selected
from the group consisting of:

N-(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)cyclopropylamide, and
N-[6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl]benzamide.

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

15. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R_2 is ~~Ar~~ phenyl, pyridyl, oxadiazolyl or thiophenyl.

16. (original) The compound according to claim 15 selected from the group consisting of:

3-(3-methyl[1,2,4]oxadiazol-5-yl)-6,6-diphenyl-6,7-dihydro-1H-indazole,

3,6,6-triphenyl-6,7-dihydro-1H-indazole,

6,6-diphenyl-3-pyrid-3-yl-6,7-dihydro-1H-indazole, and

6,6-diphenyl-3-thiophen-3-yl-6,7-dihydro-1H-indazole.

17. (currently amended) The compound according to ~~claim 4~~ claim 3 wherein R_2 is CN.

18. (currently amended) The compound according to ~~claim 14~~ claim 17 wherein the compound is 6,6-diphenyl-6,7-dihydro-1H-indazole-3-carbonitrile.

19. (original) The compound according to claim 1 wherein Z is SO_2R_3 or COR_3 .

20. (original) The compound according to claim 19 selected from the group consisting of:

6,6-diphenyl-1-(4-toluenesulphonyl)-6,7-dihydro-1H-indazol-3-ylamine and

1-(3-Amino-6,6-diphenyl-6,7-dihydroindazol-1-yl)propanone.

21. (original) The compound according to claim 1 wherein Z is 4-aminophenyl.

Application Ser. No.: 10/761,982



Filing Date: January 21, 2004

Examiner: Stockton, Laura

22. (original) The compound according to claim 21 wherein the compound is ethyl 1-(4-aminophenyl)-6,6-diphenyl-1H-indazole-3-carboxylate.

23. – 26. canceled

27. (currently amended) A method for the treatment of tumors comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (1) or formula (2)



wherein:

X and Y independently are N or CH wherein at least one of X and Y is N;

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NO₂, NH(C₁-C₄)alkyl and N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, or ~~5 or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring~~

Application Ser. No.: 10/761,982

Filing Date: January 21, 2004

Examiner: Stockton, Laura

~~together with the heteroatom to which it is attached and an ortho carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N,~~

Z is H, 4-aminophenyl, SO_2R_3 or COR_3 wherein R_3 is $(\text{C}_1\text{-C}_4)\text{alkyl}$, $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$, Ar as defined above, $(\text{C}_2\text{-C}_6)\text{alkenyl}$ or $(\text{C}_2\text{-C}_6)\text{alkynyl}$;

R_1 is H, $(\text{C}_1\text{-C}_4)\text{alkyl}$, $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ or Ar as defined above;

R' is H or $(\text{C}_1\text{-C}_4)\text{alkyl}$; and

when Z is H, R_2 is a selected from the group consisting of:

cyano,

$\text{C}(\text{O})\text{-ORa}_1$ wherein Ra_1 is methyl, ethyl or isopropyl,

$\text{C}(\text{O})\text{-NHRa}_2$ wherein Ra_2 is cyclopropyl,

$\text{C}(\text{O})\text{-N(Ra}_2')$, wherein $\text{N(Ra}_2')$ is aziridiny1 or azetidiny1, optionally substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$ or Ar as defined above,

$\text{C}(\text{O})\text{-N(Ra}_3)\text{-ORa}_3$ wherein each Ra_3 may be identical or different and each Ra_3 is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

$\text{C}(\text{O})\text{Ra}_4$ wherein Ra_4 is Ar as defined above or $(\text{C}_3\text{-C}_5)\text{cycloalkyl}$ optionally substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$ or Ar as defined above,

$\text{C(Ra}_4)\text{=N-Rb}$ wherein:

Ra_4 is H, Ar as defined above, or $(\text{C}_3\text{-C}_5)\text{cycloalkyl}$ optionally substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$ or Ar as defined above, and

Rb is $(\text{C}_1\text{-C}_2)\text{alkyl}$, $(\text{C}_3\text{-C}_5)\text{cycloalkyl}$, hydroxyl, $(\text{C}_1\text{-C}_4)\text{alkoxy}$, $(\text{C}_2\text{-C}_4)\text{alkenyloxy}$, or $(\text{C}_1\text{-C}_4)\text{alkylenoxy}$ wherein said $(\text{C}_1\text{-C}_4)\text{alkylenoxy}$ optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, $(\text{CH}_2)_n\text{Ar}$ wherein n is 0 or 1 and Ar is as defined above, $(\text{C}_1\text{-C}_4)\text{alkoxy}$, NH_2 , $\text{NH}(\text{C}_1\text{-C}_4)\text{alkyl}$, and $\text{N}((\text{C}_1\text{-C}_4)\text{alkyl})_2$ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which

Application Ser. No.: 10/761,982

Filing Date: January 21, 2004

Examiner: Stockton, Laura

may optionally contain a second hetero atom selected from the group consisting of O, S and N,

NH-C(O)Ra₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

NHRA₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above, phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and

when Z is SO₂R₃ or COR₃, R₂ is carboxyl, NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ or (C₃-C₅)cycloalkylamino; or

a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or

a ~~pharmaceutically~~ pharmaceutically acceptable salt of the compound of formula (1) or formula (2).



28. (original) The method of claim 27 wherein the therapeutically effective amount comprises an amount sufficient to inhibit microtubule polymerization.

29. (original) The method of claim 27 wherein the therapeutically effective amount comprises a therapeutically effective endothelial cell detaching amount.

30. (original) The method of claim 27 wherein the therapeutically effective amount comprises an amount sufficient to inhibit vascularization of said tumors.

Application Ser. No.: 10/761,982
 Filing Date: January 21, 2004
 Examiner: Stockton, Laura

31. (currently amended) A method for the treatment of cancerous cells comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (1) or formula (2)



wherein:

X and Y independently are N or CH wherein ~~at least one of X and Y is N;~~

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NO₂, NH(C₁-C₄)alkyl and N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, or ~~5 or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N,~~

Z is H, 4-aminophenyl, SO₂R₃ or COR₃ wherein R₃ is (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, Ar as defined above, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

R₁ is H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl or Ar as defined above;

R' is H or (C₁-C₄)alkyl; and

when Z is H, R₂ is a selected from the group consisting of:

cyano,

C(O)-ORa₁ wherein Ra₁ is methyl, ethyl or isopropyl,

C(O)-NHRa₂ wherein Ra₂ is cyclopropyl,

C(O)-N(Ra₂'), wherein N(Ra₂') is aziridinyl or azetidiny, optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

C(O)-N(Ra₃)-ORa₃ wherein each Ra₃ may be identical or different and each Ra₃ is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

C(O)Ra₄ wherein Ra₄ is Ar as defined above or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

C(Ra₄)=N-Rb wherein:

Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above, and

Rb is (C₁-C₂)alkyl, (C₃-C₅)cycloalkyl, hydroxyl, (C₁-C₄)alkoxy, (C₂-C₄)alkenyloxy, or (C₁-C₄)alkylenoxy wherein said (C₁-C₄)alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, (CH₂)_nAr wherein n is 0 or 1 and Ar is as defined above, (C₁-C₄)alkoxy, NH₂, NH(C₁-C₄)alkyl, and N((C₁-C₄)alkyl)₂ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,

NH-C(O)Ra₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

NHRa₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms
selected from the group consisting of O, N and S; and

when Z is SO_2R_3 or COR_3 , R_2 is carboxyl, NH_2 , $\text{NH}(\text{C}_1\text{-C}_4)\text{alkyl}$, $\text{N}((\text{C}_1\text{-C}_4)\text{alkyl})_2$
or $(\text{C}_3\text{-C}_5)\text{cycloalkylamino}$; or

a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures
of the stereoisomeric forms thereof in any ratio; or

a pharmaceutically pharmaceutically acceptable salt of the compound of formula
(1) or formula (2).

32. (original) The method of claim 31 wherein the therapeutically
effective amount comprises an amount sufficient to inhibit microtubule
polymerization.

33. (original) The method of claim 31 wherein the therapeutically
effective amount comprises a therapeutically effective endothelial cell detaching
amount.

34. (original) The method of claim 31 wherein the therapeutically
effective amount comprises an amount sufficient to inhibit vascularization of said
cancerous cells.

35. (original) A pharmaceutical composition comprising one or more
compounds of formula (1) or formula (2) according to claim 1 and one or more
pharmaceutically acceptable carriers, diluents, adjuvants or excipients.